Volume 2, Issue 1 (Multidisciplinary Cancer Investigation 2018)                   Multidiscip Cancer Investig 2018, 2(1): 22-25 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Jalaeikhoo H, Sharifzadeh M, Rajaeinejad M, Keyhani M, Zokaasadi M. A Tentative Staging of Multiple Myeloma by Utilizing Respective Coefficients of Prognostic Factors . Multidiscip Cancer Investig 2018; 2 (1) :22-25
URL: http://mcijournal.com/article-1-185-en.html
1- AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, Iran
2- AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, Iran , morteza.sharifzade@gmail.com
3- Hematology and Oncology Research Center, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
Abstract:   (6303 Views)
Introduction: Multiple myeloma is a heterogeneous disease with different survival times among patients. Accurate prediction of prognosis in multiple myeloma is essential, as patients with a shorter survival time may require early bone marrow transplantation (BMT) and more advanced chemotherapy as a part of their first-line treatment. In the present study, a parameter, depicted by gamma (γ) symbol, was utilized to categorize patients into different stages. Gamma value is equal to the summation of each prognostic factor multiplied by its corresponding beta coefficient. This parameter has been previously studied for the staging of some malignancies, such as “Nottingham Prognostic Index” for breast cancer and “Prognostic Score” for parotid carcinoma.
Methods: One hundred forty-three cases were randomly divided into two groups. Beta coefficients for prognostic factors, including creatinine, calcium, and albumin, were obtained from multivariate Cox analysis in the first group. In this group, a staging system based on patients’ gamma parameters was defined followed by the evaluation of the accuracy of this staging system in the second group.
Results: The staging system that developed from the first group was suitable for the prediction of outcomes in the second group. The patients of the second group were divided into approximately equal numbers in each stage comprising 29, 24, and 18 cases in stage 1, 2, and 3, respectively. In this group, the median overall survival (OS) values for patients in each stage were 92, 57, and 22 months, respectively, with log-rank = 0.002.
Conclusions: The proposed method demonstrated promising results for myeloma prognostication. The authors believe this approach would increase the strength and validity of staging of multiple myeloma.
Select article type: Short Communication | Subject: Health Services, Quality of Life and Outcomes
Received: 2017/12/12 | Accepted: 2018/01/10 | ePublished: 2018/01/15

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. [DOI] [PubMed]
2. Roy V, Greipp PR. Staging of Multiple Myeloma. In: Gertz M, Rajkumar S, editors. Multiple Myeloma. New York (NY): Springer; 2014. [DOI]
3. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al. Revised internation- al staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–9 [DOI] [PubMed]
4. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E et al. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. Hae-matologica. 2017;102(3):593–9. [DOI] [PubMed]
5. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part II: multivariate data analysisan introduction to concepts and methods. Br J Cancer. 2003;89(3):431–6. [DOI] [PubMed]
6. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC et al. A prognostic index in primary breast cancer. Br J Cancer. 1982;45(3):361–6. [DOI] [PubMed]
7. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 1987;56(4):489–92. [DOI] [PubMed]
8. Galea MH, Blamey RW, Elston CE, Ellis IO. The Notting-ham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22(3):207–19. [DOI] [PubMed]
9. Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Loftus-Coll BM, Keus RB et al. The development of a prognostic score for patients with parotid carcinoma. Cancer. 1999;85(9):2057–67. [DOI] [PubMed]
10. Poorten VV, Hart A, Vauterin T, Jeunen G, Schoenaers J, Hamoir M et al. Prognostic index for patients with parotid carcinoma: international external validation in a Belgian-German database. Cancer. 2009 F;115(3):540–50. [DOI] [PubMed]
11. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–54. [DOI] [PubMed]
12. Merlini G, Waldenström JG, Jayakar SD. A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood. 1980;55(6):1011–9. [PubMed]
13. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J et al. International staging system for multiple myeloma. J Clin Oncol. 2003;78 (1):21-33. [DOI] [PubMed]
14. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78 (1):2133. [DOI] [PubMed]
15. Qian J, Jin J, Luo H, Jin C, Wang L, Qian W et al. Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases. Hematology. 2017;22(8):472–6. [DOI] [PubMed]
16. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994;69 (6):979-85. [PubMed]
17. Vander Poorten VLM. Salivary Gland Carcinoma: Stepping Up the Prognostic Ladder: Universiteit van Amsterdam [Host]; 200

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Multidisciplinary Cancer Investigation

Designed & Developed by : Yektaweb